STOCK TITAN

Alector Stock Price, News & Analysis

ALEC Nasdaq

Welcome to our dedicated page for Alector news (Ticker: ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.

Alector, Inc. (ALEC) is a clinical-stage biotechnology leader pioneering immuno-neurology therapies targeting Alzheimer’s, Parkinson’s, and related neurodegenerative diseases. This page serves as the definitive source for official company announcements, research breakthroughs, and partnership developments.

Investors and researchers will find curated updates on clinical trial progress, regulatory milestones, and scientific publications. Our aggregation includes press releases about therapeutic candidates like AL001 (TREM2 agonist) and AL002, plus updates on the proprietary ABC platform enhancing drug delivery.

Key content categories cover phase trial results, collaboration agreements with major biopharma partners, and peer-reviewed study data. All materials are sourced directly from Alector’s communications to ensure accuracy and timeliness.

Bookmark this page for streamlined access to Alector’s latest developments in immune system modulation for brain health. Check regularly for updates on their innovative approach to combating neurodegeneration through validated genetic targets and advanced therapeutic engineering.

Rhea-AI Summary

Alector, Inc. (Nasdaq: ALEC) reported promising outcomes from its Phase 2 INFRONT-2 study of AL001, targeting frontotemporal dementia (FTD) due to progranulin gene mutations. At the Alzheimer’s Association International Conference, data showed that AL001 restored progranulin to normal levels and slowed clinical progression by 47% compared to a matched control group. Safety results indicated a favorable profile with mild adverse effects in a small patient cohort. Alector plans to proceed with a Phase 3 study, further assessing AL001's efficacy and safety in FTD patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.08%
Tags
-
Rhea-AI Summary

Alector, Inc. (Nasdaq: ALEC) announced an oral presentation on July 29, 2021, regarding the Phase 2 study of AL001 for frontotemporal dementia with a progranulin mutation, at the 2021 Alzheimer’s Association International Conference. The six- and twelve-month data from the open-label INFRONT-2 study will be discussed by Dr. Robert Paul, CMO. Additionally, two posters will present the AL002 Alzheimer’s disease program, including Phase 1 study results and INVOKE-2 trial design. The conference call will be held at 1:00 p.m. ET to review findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.89%
Tags
conferences
-
Rhea-AI Summary

Alector and GSK have formed a strategic collaboration to co-develop monoclonal antibodies AL001 and AL101 aimed at treating multiple neurodegenerative diseases. This partnership includes a $700 million upfront payment and up to $1.5 billion in potential milestones. Alector will lead clinical development up to Phase 2, while both companies will share commercialization responsibilities in the U.S., with GSK handling international rights. The collaboration could significantly expand treatment options for conditions like frontotemporal dementia, ALS, Parkinson's, and Alzheimer’s.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
57.12%
Tags
none
Rhea-AI Summary

Alector, a clinical-stage biotechnology company specializing in immuno-neurology, announced that Dr. Shehnaaz Suliman will participate in two upcoming investor conferences. The events include the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 4:40 p.m. ET, and the BofA Securities 2021 Napa Biopharma Virtual Conference on June 14, 2021, at 5:30 p.m. ET. Live webcasts will be accessible on Alector's website, with replays available for 30 days post-event. Alector is focused on developing therapies for neurodegenerative diseases by targeting immune dysfunction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
conferences
-
Rhea-AI Summary

Alector, Inc. (Nasdaq: ALEC) announced a virtual key opinion leader event on frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) scheduled for June 11, 2021, at 10:30 a.m. ET. The agenda includes discussions on FTD-GRN pathophysiology, clinical endpoints, and disease-relevant biomarkers. Key presentations will be made by esteemed neurology experts, including Henrik Zetterberg and Jonathan Rohrer. The event will be webcast live on Alector's website. AL001, an investigational monoclonal antibody for FTD-GRN, has received Orphan Drug and Fast Track designations from the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
conferences
-
Rhea-AI Summary

Alector, a clinical-stage biotechnology company specializing in immuno-neurology, announced participation by its president and COO, Shehnaaz Suliman, in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 11:45 a.m. ET. A live webcast will be accessible on the Alector website, with a replay available for 30 days post-event. Alector focuses on innovative therapies for neurodegenerative diseases, emphasizing innate immune system repair and targeting genetic mutations in neurodegenerative conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
conferences
Rhea-AI Summary

Alector, Inc. (Nasdaq: ALEC) reported key business updates and financial results for Q1 2021. The company is actively enrolling patients in the AL001 INFRONT-3 Phase 3 trial for frontotemporal dementia and the AL002 INVOKE-2 Phase 2 trial for early Alzheimer's disease. Collaboration revenue dropped to $4.1 million from $7.2 million year-over-year. R&D expenses rose significantly to $45.7 million, contributing to a net loss of $52.2 million, up from $40 million in Q1 2020. Cash, cash equivalents, and marketable securities totaled $362.7 million as of March 31, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.02%
Tags
-
Rhea-AI Summary

Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced that its president, Shehnaaz Suliman, will participate in a fireside chat at Stifel’s 3rd Annual CNS Day on April 1, 2021, at 9:30 a.m. ET. The event will be accessible via a live webcast on the Alector website, with a replay available for 30 days afterward. Alector is pioneering treatments for neurodegenerative diseases by targeting immune dysfunction, particularly in Alzheimer's and frontotemporal dementia patient populations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
conferences
-
Rhea-AI Summary

Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on immuno-neurology, announced participation in the Barclays Global Healthcare Conference on March 11, 2021, at 2:25 p.m. ET by COO Shehnaaz Suliman, M.D. A live webcast will be available on Alector's Investors page, with a replay accessible for 30 days post-event. Alector is developing innovative therapies targeting neurodegenerative diseases, utilizing innate immune system programs to address immune dysfunction in conditions like Alzheimer's and frontotemporal dementia. Visit www.alector.com for more information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.05%
Tags
conferences
Rhea-AI Summary

Alector, Inc. (NASDAQ: ALEC) reported business updates and financial results for Q4 2020, highlighting significant progress in its clinical programs. The company initiated the AL001 INFRONT-3 Phase 3 trial for frontotemporal dementia and AL002 INVOKE-2 Phase 2 trial for early Alzheimer's disease. Revenue for Q4 was $4.9 million, down from $6.0 million YoY, with a total 2020 revenue of $21.1 million, relatively stable. R&D expenses surged to $44.4 million for Q4, contributing to a net loss of $52.2 million. Alector's cash position remains strong at $413.3 million, sufficient to fund operations through mid-2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags

FAQ

What is the current stock price of Alector (ALEC)?

The current stock price of Alector (ALEC) is $1.51 as of July 3, 2025.

What is the market cap of Alector (ALEC)?

The market cap of Alector (ALEC) is approximately 150.0M.
Alector

Nasdaq:ALEC

ALEC Rankings

ALEC Stock Data

149.99M
89.55M
13.37%
83.09%
5.57%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO